Gilder Gagnon Howe & Co. LLC reduced its position in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,126 shares of the medical equipment provider’s stock after selling 950 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Boston Scientific Corporation were worth $1,279,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quadrant Capital Group LLC increased its position in shares of Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 487 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares during the last quarter. Guardian Life Insurance Co. of America increased its position in shares of Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares during the last quarter. Commerce Bank purchased a new position in shares of Boston Scientific Corporation during the first quarter worth about $207,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Boston Scientific Corporation during the first quarter worth about $215,000. 92.08% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Boston Scientific Corporation (NYSE BSX) opened at 26.26 on Friday. The firm’s 50-day moving average is $27.38 and its 200 day moving average is $26.02. The firm has a market capitalization of $36.03 billion, a PE ratio of 46.98 and a beta of 1.09. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.27 earnings per share. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Gilder Gagnon Howe & Co. LLC Has $1.28 Million Stake in Boston Scientific Corporation (NYSE:BSX)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/gilder-gagnon-howe-co-llc-has-1-28-million-stake-in-boston-scientific-corporation-nysebsx/1472954.html.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. UBS AG reaffirmed a “buy” rating and issued a $31.00 price objective (up previously from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. BidaskClub downgraded shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Boston Scientific Corporation in a research report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation has a consensus rating of “Buy” and a consensus target price of $30.06.

In other news, SVP Wendy Carruthers sold 12,433 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin J. Ballinger sold 28,864 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total transaction of $754,504.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 236,489 shares of company stock worth $6,440,888. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.